Generic Name and Formulations:
Latanoprostene bunod 0.024%; oph soln; contains benzalkonium chloride.
Valeant Pharmaceuticals, Inc
Indications for VYZULTA:
Open-angle glaucoma. Ocular hypertension.
>16yrs: instill 1 drop in the affected eye(s) once daily in the PM.
≤16yrs: not recommended.
Do not exceed recommended dose (may reduce efficacy). History of ocular inflammation: not recommended if active inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Bacterial keratitis may occur (due to multiple-dose containers). Contact lenses (remove; may reinsert lenses 15mins after administration). Pregnancy. Nursing mothers.
Allow at least 5mins between application of other topical oph agents.
Conjunctival hyperemia, eye irritation, eye pain, instillation site pain; increased ocular pigmentation (eg, iris [may be permanent], eyelid, eyelashes), other eyelash/lid changes, macular edema (including cystoid macular edema).
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- Psychological Therapies May Help Older Adults With Chronic Pain
- Traumatic Brain Injury Linked to Increased Parkinson Disease Risk in Veterans
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics